Target-Vessel Failure Rate Similar for Scaffold, Stent in PCI

This article originally appeared here.
Share this content:
Target-Vessel Failure Rate Similar for Scaffold, Stent in PCI
Target-Vessel Failure Rate Similar for Scaffold, Stent in PCI

THURSDAY, March 30, 2017 (HealthDay News) -- For patients undergoing percutaneous coronary intervention (PCI), the rate of target-vessel failure does not differ significantly for those receiving a bioresorbable vascular scaffold or a metallic stent, according to a study published online March 29 in the New England Journal of Medicine.

Joanna J. Wykrzykowska, M.D., Ph.D., from the Academic Medical Center-University of Amsterdam, and colleagues randomized patients undergoing PCI to receive a bioresorbable vascular scaffold or a metallic stent (924 and 921 patients, respectively). Target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization) was assessed as the primary end point.

The researchers found that the two-year cumulative event rates for target-vessel failure were 11.7 and 10.7 percent in the scaffold and stent groups, respectively (hazard ratio, 1.12; 95 percent confidence interval, 0.85 to 1.48; P = 0.43). The two-year cumulative event rates were 2.0 and 2.7 percent, respectively, for cardiac death; 5.5 and 3.2 percent, respectively, for target-vessel myocardial infarction, and 8.7 and 7.5 percent, respectively, for target-vessel revascularization. The two-year cumulative event rates were 3.5 and 0.9 percent for the scaffold and stent groups, respectively, for definite or probable device thrombosis (hazard ratio, 3.87; 95 percent confidence interval, 1.78 to 8.42; P < 0.001).

"There was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent," the authors write.

The study was funded by Abbott Vascular.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Approves Admelog for Diabetes

FDA Approves Admelog for Diabetes

First drug approved as a follow-up product based on an abbreviated new process

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

Mean change in Unified Parkinson's Disease Rating Scale motor score lower for high-intensity exercise

is free, fast, and customized just for you!

Already a member?

Sign In Now »